Company: CERO
Filing Date: 2025-05-27
Form Type: POS AM
Source: 0001213900-25-047469
Chunk: 402

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-27
Form: POS AM
Chunk 402
---
 which the director derived an improper personal benefit. II-1 Additionally, our Charter and Bylaws limit the liability of our (i) directors and (ii) officers, which includes each individual who has been duly appointed as an officer of CERo and who, at the time of an act or omission as to which liability is asserted, is deemed to have consented to service of process to our registered agent as contemplated by Section 3114(b) of Title 10 of the DGCL, in each case, to the fullest extent permitted by the DGCL, and also provides that we indemnify our directors and officers to the fullest extent permitted by the DGCL. In connection with the Closing, we entered into indemnification agreements with each of our directors and executive officers. These agreements provide that we indemnify each of our directors and officers to the fullest extent permitted by law and our Charter and Bylaws, and provides for advancement of expenses incurred as a result of any proceeding against them as to which they could be indemnified. We also maintain a general liability insurance policy, which covers certain liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers. Item 15. Recent Sales of Unregistered Securities. In February 2024, May 2024 and August 2024, we issued 1,191, 2,504 and 16,139 shares of Common Stock, respectively, to an investor as commitment shares in consideration for entering into an equity line of credit with us. The issuance of these securities was made pursuant to Section 4(a)(2) of the Securities Act, and the rules promulgated thereunder, to an accredited investor. As of the date of this prospectus, we have issued an aggregate of 644,966 shares of Common Stock to such investor pursuant to the equity line of credit. In February 2024, we issued an aggregate of 10,089 shares of Series A Preferred Stock, at a price of $1,000 per share, initially convertible into 10,089 shares of Common Stock at $10.00 per share, and 2,500 Preferred Warrants, resulting in aggregate consideration to us of approximately $10.0 million. Such issuance includes 2,185 shares of Series A Preferred Stock, initially convertible into 2,185 shares of Common Stock, that were issued to certain investors in exchange for consideration consisting of approximately $2.16 million aggregate outstanding principal amount, together with accrued and unpaid interest there